Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

St. Jude Medical learns hard digital lessons with CardioMEMS

November 2, 2015 By Heather Thompson

St. Jude Medical's CardioMEMS implantable heart monitorAs a device part of what some call the healthcare revolution, CardioMEMs HF from St. Jude Medical ticks all the boxes. It is the first permanent diagnostic cardiovascular implant, and a big deal in terms of developing the digital healthcare market.

The device enables mobile monitoring of patients at risk for heart failure. It works wirelessly, and transmits data to healthcare providers to protect patients while they are at home, with the aim at reducing hospitalization. CardioMEMS HF System features a sensor that is implanted in the pulmonary artery (PA) during a non-surgical procedure to directly measure PA pressure. Increased PA pressures appear before weight and blood pressure changes, which are often used as indirect measures of worsening heart failure. Through the system, patients transmit daily sensor readings to health care providers. This level of personalization should anticipate health problems, reducing a patient’s need to be hospitalized.

In the marketplace, however, the device has run up against some challenges, and from the beginning, it’s been a lukewarm reception. In 2013, FDA relied on an advisory panel to assess the product before approval.  Most of the Circulatory System Devices panel agreed on the device’s safety, but had continued questions on the product efficacy. Nonetheless, the committee wanted the product to move forward by a narrow vote of 6-4 in favor, saying that the benefits of the product likely outweighed its risks. FDA approved the product in May 2014, noting that it would “continue to learn about the device’s performance when used outside the context of a clinical study.” I accept the nature of FDA and advisory panels to use careful language, particularly with new products, but this seems more like barely passable analysis from the agency.

In the last few months, the product has taken some hits. The company says insurers are objecting the product’s use. CEO Daniel Starks spoke about the challenge during SJM’s in a quarterly earnings call on Oct 21. “There’s a lot of resistance to uptake of new technology in the payer environment,” he said, according to a Seeking Alpha transcript. “Our challenge is to fight through just a natural inertia and resistance to pay for new technology and to educate people fully that this technology is one of the good guys. It’s … not something that adds to the cost of healthcare. It’s something that really reduces the cost of healthcare.”

In September, the Institute for Clinical and Economic Review (ICER) released a draft report concluding that CardioMEMS HF represented a “small net benefit” compared with alternatives to monitoring patients with heart failure risk. The ICER report also skewered the price of the product at $17,750 as “excessive.”
 SJM had already defended its pricing scheme. In March, medical director and vice president of medical affairs Philip Adamson presented the company’s cost analysis data at the Heart Rhythm Society’s Scientific Sessions. Following the ICER report, Adamson discussed it again in October at AdvaMed’s annual meeting, saying that the price of the system fits within typical healthcare economic evaluations and is “defensible.”

The latest wrinkle for SJM is its Atlanta manufacturing plant, where the CardioMEMS HF products are made. FDA issued a warning to the company about the Atlanta facility, noting nonconformities to good manufacturing practices on September 30. The agency said the plant failed to meet deadlines to address concerns about incorrect serial numbers, device surface coating defects, and validation of the sterilization process. SJM has clarified that these concerns do not involve the performance of CardioMEMS. Nonetheless, it feels like another negative in the CardioMEMS column, and there is no doubt that mass media is making a connection.

The lessons: In the new digital healthcare market, everyone – including FDA – is working to find the best way to navigate. It could be that FDA and insurers are going to be particularly difficult on companies that try to get new technologies on the market. The market success of CardioMEMS rests squarely on its ability to influence and educate the many stakeholders on the value of the technology.

I spoke with Michael Drues, president of Vascular Sciences, for regulatory advice for companies who are also developing digital healthcare products. Drues is a published author and has served as an advisory panel member for FDA on multiple occasions (Drues is also the regulatory consultant for a company developing a product that will directly compete with CardioMEMS).

Here are the pointers he had for companies:

  • Don’t think of the regulatory structure for digital products differently than you would for any other medical device. The basic tenets are the same.
  • Don’t just get do the regulatory minimum to pass. In fact, don’t even think about the regulatory structure for safety and efficacy. Think about the fact that one day, you, your mother, or your son, might need a device. What would be your acceptable safety and efficacy levels?
  • Don’t think of regulation in isolation. You have to make it part of the reimbursement, quality, and manufacturing structures. It is all connected.
  • Involve FDA is discussions early on and before you submit your PMA or 510(k). If you send a submission with the expectation of getting questions back, you are moving in the wrong direction and wasting money. Get those questions from FDA and include the answers in your submission.

Most importantly for other companies who are also developing digital products: Don’t move too fast. In the new technology market, maybe it’s best to be second.

Related Articles Read More >

An illustration of Embolization Inc.'s Nitinol Enhanced Device (NED).
This nitinol vascular embolization device has another shape memory material up its sleeve
A photo of nitinol, a nickel-titanium alloy used for medical devices such as stents, heart valves, catheters and orthopedics.
What is nitinol and where is it used?
July 2025 edition: The Surgical Robotics issue, featuring Capstan Medical, J&J and Zimmer Biomet
A photo of Capstan Medical's mitral valve implant, which uses nitinol.
Capstan Medical’s R&D head discusses the heart valve and robotics startup’s tech, engineering challenges and solutions, advice for others in medtech and how to join his team
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Educational Assets
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Views
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe